Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Is Vertex Pharmaceuticals Stock a Buy?
Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about

2 Beaten-Down Stocks That Still Aren't Worth Buying
2 Beaten-Down Stocks That Still Aren't Worth Buying

President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for

1 Safe Stock to Buy as Tariffs Trigger Market Crash
1 Safe Stock to Buy as Tariffs Trigger Market Crash

There's no such thing as a completely "safe" stock, but some stocks are less risky than others. That's particularly true during times of extreme uncertainty and volatility. The major stock indices

AMD Stock Investors Got Amazing News on Nvidia
AMD Stock Investors Got Amazing News on Nvidia

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and recent updates investors should know. To learn more, check out the short video, consider subscribing, and click the special offer

Down 62%, Should You Buy the Dip on Pfizer?
Down 62%, Should You Buy the Dip on Pfizer?

Pharmaceutical giant Pfizer (NYSE: PFE) was a big winner during the COVID-19 pandemic. Its vaccine and antiviral pill generated billions of dollars in sales. However, that revenue source has largely

27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks

Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average

2 Stocks to Buy if You're Worried About a Recession
2 Stocks to Buy if You're Worried About a Recession

Is a recession coming? Our economic outlook seems increasingly gloomy due to President Trump's trade policies. Though things might not go that far, it's still worth planning ahead.

If a recession

Why Applovin Plunged in March
Why Applovin Plunged in March

Shares of digital advertising up-and-comer Applovin (NASDAQ: APP) plunged 18.2% in March, according to data from S&P Global Market Intelligence.

Applovin already had a rough February, when it was

Prediction: Taiwan Semiconductor Manufacturing Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Prediction: Taiwan Semiconductor Manufacturing Will Soar Over the Next 5 Years. Here's 1 Reason Why.

Taiwan Semiconductor Manufacturing (NYSE: TSM) is the world's leading semiconductor (chip) foundry. Its foundry business model means it makes chips tailored to its customers' specific needs, and key

Is This Artificial Intelligence IPO a Buy?
Is This Artificial Intelligence IPO a Buy?

Although recent stock market volatility has pushed down prices for many stocks, the artificial intelligence (AI) sector remains a compelling investment, with the tremendous transformative potential

2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade

Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the

3 Dividend Stocks to Buy and Hold for the Next Decade
3 Dividend Stocks to Buy and Hold for the Next Decade

What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.

Three Motley Fool contributors think they've found great dividend stocks to own

2 Dividend Stocks to Buy Hand Over Fist in April
2 Dividend Stocks to Buy Hand Over Fist in April

One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years

Three stocks which have generated 100-bagger returns for investors over the past 20 years are Booking Holdings (NASDAQ: BKNG), Apple (NASDAQ: AAPL), and Regeneron Pharmaceuticals (NASDAQ: REGN)

EQS-News: Sartorius to acquire microtissue business MatTek from Swedish BICO AB : https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-News: Sartorius to acquire microtissue business MatTek from Swedish BICO AB
EQS-News: Sartorius to acquire microtissue business MatTek from Swedish BICO AB
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst

3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months

Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025. Whether that's due to its high valuation, concerns about the

This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years

There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all

Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers

The Smartest Biotech Stocks to Buy With $50
The Smartest Biotech Stocks to Buy With $50

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share

Is Pfizer Stock a Buy?
Is Pfizer Stock a Buy?

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the

Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy is worrisome, as trade wars and promised tariffs could lead to disaster

2 Absurdly Cheap Stocks to Buy and Hold for Years
2 Absurdly Cheap Stocks to Buy and Hold for Years

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still

AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2024
AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2024
AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2024
2 Beaten-Down Stocks to Buy and Hold for a Decade
2 Beaten-Down Stocks to Buy and Hold for a Decade

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key is to purchase shares of robust companies, occasionally adding more, and